Subscribe
Home
Issues
Latest Issue
Issue Archive
Special Issues
Categories
Web Exclusives
Web Exclusive Articles
Webinars
Search ...
Alzheimer’s Disease/Dementia
Methylphenidate Modestly Improved Apathy in Patients with Alzheimer’s Disease
Alzheimer’s Disease/Dementia
July 2022
In patients with Alzheimer’s disease with clinically significant apathy, treatment with methylphenidate for 6 months in ADMET 2 was associated with a modest improvement in apathy.
Read More
Depression and the Risk of Alzheimer's Disease in Older Adults
Alzheimer’s Disease/Dementia
June 2022
A retrospective cohort study found that newly diagnosed depression increased the risk of Alzheimer’s disease in older individuals, especially when the depression was severe.
Read More
Age of Onset of Type 2 Diabetes and the Risk of Dementia
Alzheimer’s Disease/Dementia
May 2022
In patients with type 2 diabetes, a younger age of onset is associated with an increased risk of developing dementia.
Read More
Use of Mirtazapine for Reducing Agitation in Dementia
Alzheimer’s Disease/Dementia
April 2022
According to the recent Study of Mirtazapine for Agitated Behaviors in Dementia (SYMBAD) trial, there was no improvement in agitation in patients with Alzheimer disease taking mirtazapine compared with placebo. Furthermore, the treatment group had more deaths than the placebo group, and the investigators suggested that mirtazapine should no longer be used for agitation in patients with dementia.
Read More
Predicting the Onset of Alzheimer Disease Symptoms
Alzheimer’s Disease/Dementia
March 2022
Researchers developed a model to predict when cognitively unimpaired individuals who have brain amyloidosis would develop symptoms of Alzheimer dementia using positron emission tomography scans for amyloid accumulation.
Read More
Relapse in Patients with Dementia-Related Psychosis After Discontinuation of Pimavanserin
Alzheimer’s Disease/Dementia
February 2022
Discontinuation of pimavanserin for dementia-related psychosis was associated with a higher rate of relapse compared with continuation, according to a recent randomized discontinuation trial that was stopped early for efficacy.
Read More
Dementia Risk Rises in Some Women with Use of Calcium Supplements
By
Charles Bankhead
Alzheimer’s Disease/Dementia
Web Exclusives
Elderly women with cerebrovascular disease had a significantly increased risk for dementia if they took calcium supplements, a retrospective analysis of 2 studies showed.
Read More
Idalopirdine Improves Cognition in Patients with Moderate Alzheimer’s Disease
By
Chase Doyle
Alzheimer’s Disease/Dementia
VBCN - November 2016 Volume 3, No 3
A phase 2 clinical trial of the investigational agent idalopirdine (Lu AE5854), a selective 5-HT
6
receptor antagonist, as adjunctive treatment to the cholinesterase inhibitor donepezil has demonstrated improved cognition in patients with mild-to-moderate Alzheimer’s disease. The results also showed a trend toward ameliorating declines in function and global clinical status, researchers reported at the 2016 American Academy of Neurology annual meeting.
Read More
Pro and Con: Do Cognitive-Enhancing Activities Prevent Dementia?
By
Chase Doyle
Alzheimer’s Disease/Dementia
VBCN - November 2016 Volume 3, No 3
In a series of debates at the 2016 American Academy of Neurology annual meeting, expert physicians debated current and controversial issues in neuroscience. David S. Knopman, MD, FAAN, Professor of Neurology, Alzheimer’s Disease Research Center, Mayo Clinic, Rochester, MN, advocated for the benefits of cognitive-enhancing activities; Kaycee M. Sink, MD, MAS, Medical Director, Kulynych Memory Assessment Clinic, Wake Forest Baptist Medical Center, Winston-Salem, NC, contended that there is a lack of controlled studies to guide clinical recommendations.
Read More
Alzheimer’s Prevention Clinic: A New Approach to Disease Management Shows Benefits
By
Chase Doyle
Alzheimer’s Disease/Dementia
VBCN - November 2016 Volume 3, No 3
The Alzheimer’s Prevention Clinic, a specialized program that focuses on the latest treatments for patients with Alzheimer’s disease and state-of-the-art prevention strategies, is helping to reduce the risks associated with the disease. With an emphasis on nutritional approaches, patients at the program receive a personalized plan based on risk factors, genes, medical conditions, and the latest scientific research.
Read More
Page 1 of 2
1
2
Search ...
Home
Issues
Latest Issue
Issue Archive
Special Issues
Categories
Web Exclusives
Web Exclusive Articles
Webinars
Subscribe to
Value-Based Care in Neurology
Stay up to date with personalized medicine by subscribing to receive the free
VBCN
e‑Newsletter.
I'd like to receive:
VBCN
e‑Newsletter
I have reviewed and consent to the terms of
VBCN
's
Privacy Policy
, and
VBCN
has my permission to retain my information in its database, and to forward pertinent communications to me.